
Deloitte

Future of Customer Engagement in Pharma

Insights from the European region



Executive Summary | Existing engagement approaches lead to a gap between HCPs and corporate expectations, driven by strategy, content, and channels



Context and objectives | European HCPs & EU Executives Pharma Surveys

CONTEXT

- In today's rapidly evolving pharmaceutical landscape, understanding the future of customer engagement is crucial for meeting the needs and expectations of HCPs
- Deloitte conducted a comprehensive survey targeting the preferences and expectations of HCPs in Europe regarding their interactions with pharmaceutical companies
- A separate survey of pharma executives was conducted to explore the industry's perspective on future customer engagement and the gaps between their perception and HCP needs

OBJECTIVES

- **Understand HCP Preferences:** Determine preferred methods and channels for HCPs to receive information from pharmaceutical companies.
- **Assess Current Interactions:** Evaluate how effectively pharmaceutical companies are currently meeting the needs and expectations of HCPs in their interactions.
- **Uncover Unmet Needs:** Identify any gaps or unmet needs in the current engagement strategies of pharmaceutical companies.
- **Prioritise Enablers:** Focus on key enablers to unlock the full potential of pharma customer engagement pillars.



Elevate Customer Engagement Capabilities: Build new capabilities or strengthen existing ones to bridge the gap between pharma businesses and their customers.

SCOPE OF THE SURVEYS



HCPs: UK, Spain, France, Germany Pharma: EU region



HCPs: 19 Questions Pharma: 4 Questions




HCPs: 61 from different specialities Pharma: 17 executives The **foundational pillars** were thoroughly assessed in the **European surveys** of HCPs and Pharma Executives



Customer Engagement Models






The EU HCP Survey examines 3 customer engagement pillars to address unmet needs, evaluate current interactions & enhance understanding of HCP preferences

CX Strategy

Content


Channels



Channels

Content

The EU HCP Survey highlights a critical need to boost personalized engagement through awareness, clinical data, and MSL interactions



Content

Channels

Crafting a winning customer experience needs a customer-centric & valuebased engagement that truly shifts towards data-driven

SS CV Stratogy	Data insights		Key questions		Actions to address these questions	
"Focus on a customer- centric approach rather than a product-centric approach."	#1	The #1 improvement to engagement is to demonstrate the effectiveness of treatments to HCPs ⁵	How can the effectiveness of treatments be better demonstrated to HCPs?	c	nsure effective communication of linical data through content, channels, ormats, tone, and interaction frequency	
"Value-based engagement, focusing on delivering meaningful content and experiences aligned with customer values."7	52%	of HCPs believe that Pharma companies should interact across all stakeholders to build advocacy and communicate both branded and unbranded messages ⁵	How can interactions be enhanced to effectively communicate both branded and unbranded messages?	St	evelop an integrated strategy with takeholder collaboration to drive HCP doption through omnichannel interactions	
"Shift towards data-driven insights and cross-channel integration for a customized experience." ⁷	67%	of HCPs believe pharma engagement should drive high patient awareness about health issues ⁵	How can disease awareness be effectively driven through engagement with HCPs?	e a	ollaborate with HCPs to create and share ducational campaigns on disease wareness using digital and traditional nedia	
	16 out of 17	of Pharma executives believe Marketing and Sales will drive customer engagement over the next 5 years, but HCPs value medical channels, making Medical functions crucial ⁵	How can cross-function team be balanced to optimize customer engagement?	co e	orm a cross-functional team to create a ohesive engagement plan that leverages ach function's strengths and meets HCP references	

Content

Creating impactful, easy-to-understand & personalized content that is adapted to the right context will be pivotal to drive meaningful customer engagement

Data insights		Key questions		Actions to address these questions	
#1	The top piece of information HCPs regularly seek is clinical data ⁵ , which they get from non-pharma channels 79% of the time ⁵	How can we create relevant content that can be reused and scaled?	>	Use a modular content approach with reusable components for consistent, efficient, personalized, and scalable content creation and distribution	
34%	of HCPs say reps don't tailor their messages and are ineffective in telling the scientific story ⁵	How can we meet HCPs expectations?	>	Focus on delivering integrated, personalized experiences to meet HCPs' changing expectations by leveraging Generative AI for precise, up-to-date information	
					56%
80%	of HCPs consider educational programs at least somewhat effective or very effective ; none of the HCPs considered these programs as not effective ⁵	How do I ensure content is compliant?	>	Streamline MLR approval process by leveraging Al, automating compliance and quality checks, ensuring accuracy	
		 #1 <i>The top piece of information HCPs regularly seek is clinical data</i>⁵, which they get from non-pharma channels 79% of the time⁵ of HCPs say reps don't tailor their messages and are ineffective in telling the scientific story⁵ of HCPs regularly seek for information on "new innovations"⁵ of HCPs regularly seek for information on "new innovations"⁵ 	 #1 The top piece of information HCPs regularly seek is clinical data⁵, which they get from non-pharma channels 79% of the time⁵ Mow can we create relevant content that can be reused and scaled? Mow can we meet HCPs expectations? Mow can we meet HCPs expectations? Mow can we create compelling of HCPs regularly seek for information on "new innovations"⁵ Mow can we create compelling content with flexibility, consistency and efficiency at scale? Mow can we create compelling content with flexibility, consistency and efficiency at scale? Mom can we create compelling content with flexibility, consistency and efficiency at scale? Mom can we create compelling content with flexibility, consistency and efficiency at scale? 	 #1 The top piece of information HCPs regularly seek is clinical data⁵, which they get from non-pharma channels 79% of the time⁵ Mow can we create relevant content that can be reused and scaled? of HCPs say reps don't tailor their messages and are ineffective in telling the scientific story⁵ How can we meet HCPs expectations? of HCPs regularly seek for information on "new innovations"⁵ of HCPs consider educational programs at least somewhat effective or very effective; none of the HCPs considered 	

Content

Channels

Maximizing customer engagement with strong tech-enabled channel integration, with an enhanced focus on digital channel expansion


	Data insights		Key questions	Actions to address these questions	
"Strong partnership with major opinion leaders and healthcare providers will allow	#1	The most valuable interaction with pharma companies for HCPs are pharma-sponsored events (e.g., seminars/webinars) ⁵	Do we leverage multiple channels to enhance the value and impact of pharma-sponsored events?	Develop a cohesive channel integration strategy to amplify the reach and impact of events , ensuring personalized and relevant communications	
you to meet more needs that correspond to demand" ⁶ "Switching from in person events to digital experiences " ⁶	42%	of HCPs emphasised as their primary challenge with MSLs that they didn't interact with them enough ⁵	, Are we effectively considering HCPs' preferred communication channels?	Segment HCPs by channel preference to tailor communication strategies accordingly and ensure that HCP interactions with pharmaceutical representatives occur with whom they prefer and when they prefer	
" Expand their digital channels with their own digital strategy to have the best results in the industry" ⁶	52%	of HCPs would prefer quarterly interactions with sales representatives ⁵	Are we making the best use of HCP interactions with pharma representatives?	Integrate channels technology to track and analyze HCP-pharma representatives' interactions, identifying patterns and opportunities for personalized, impactful engagements	
	64%	of HCPs considered social media at least a moderately valuable channel for engagement ⁵	, How can we optimize channels to for effective communication and enhanced customer experience?	Focus on accessible, consistent channels like webinars, social media, HCP portals, and digital platforms. Use analytics to track engagement and refine strategies based on feedback and performance data	

The **enablers** are essential for unlocking the full potential of Future of Customer Engagement




Customer Engagement Models





Technology

Three pivotal enablers supplement the foundational pillars to bolster the required capability building and addressing the customer engagement gaps




Deloitte's 5 distinct research-backed Future Customer Engagement Models with differentiated focus on foundational pillars & enablers can help companies prioritize capabilities and investments




Customer Engagement Models






Our Future Customer Engagement Models have a clear, differentiated focus on various required capabilities relevant to your organizational needs



Each Customer Engagement Model is unique and interacts with the foundational pillars and enablers of customer engagement in distinct ways



Deloitte.

Footnotes:

1. The industry is falling short based on customer engagement perception gap between LS executives and HCPs needs. | 2. Data taken from Deloitte pharma executives survey. | 3. Deloitte HCP EU survey: On a scale of 1 (not satisfied): values 4 and 5 indicate "satisfied", values 1 and 2 "not satisfied", and 3 "neutral". | 4. Deloitte HCP EU survey. | 6. Quotes taken from Deloitte HCPs survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloitte pharma executives survey. | 7. Quotes taken from Deloit

This publication has been written in general terms and we recommend that you obtain professional advice before acting or refraining from action on any of the contents of this publication. Deloitte Consulting AG accepts no liability for any loss occasioned to any person acting or refraining from action as a result of any material in this publication.

Deloitte Consulting AG is an affiliate of Deloitte NSE LLP, a member firm of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"). DTTL and each of its member firms are legally separate and independent entities. DTTL and Deloitte NSE LLP do not provide services to clients. Please see <u>www.deloitte.com/ch/about</u> to learn more about our global network of member firms.

© 2024 Deloitte Consulting AG. All rights reserved.